Three-month depot of goserelin acetate: Clinical efficacy and endocrine profile

Urology

Volumn 48, Issue 6, 1996, Pages 894-900

  Fernandez Del Moral, Pilar ^a,b,c   Dijkman, Gerhard A ^a,b,c   Debruyne, Frans M J ^a,b,c   Witjes, Wim P J ^a,b,c   Kolvenbag, Geert J M C ^a,b,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Ignatius Hospital   (Netherlands)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GOSERELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; GOSERELIN; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TESTOSTERONE; TIME FACTORS;

EID: 0030466914     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00300-7     Document Type: Article

References (8)

1. 1. Lange PH, and Brawer MK: Changing time for prostate cancer management. Contemp Urol 3: 54-56, 61-64, 1991.
2. 2. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, and Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424, 1989.
3. 3. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, and Kolvenbag G: A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 45: 745-752, 1995.
4. 4. Dijkman GA, Fernandez del Moral P, Plasman JWMH, Kums JJM, Delaere KPJ, Debruyne FMJ, Hutchinson FJ, and Furr BJA: A new extra long acting depot preparation of the LHRH analogue Zoladex: first endocrinological and pharmacokinetic data in patients with advanced prostate cancer. J Steroid Biochem Mol Biol 37: 933-936, 1990.
5. 5. Dijkman GA, Debruyne FMJ, Fernandez del Moral P, Plasman JW, Hoefakker JW, Idema JG, and Sykes M: A randomized trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. Eur Urol 27: 43-46, 1995.
6. 6. Debruyne FMJ, Dijkman GA, Lee DCH, and Witjes WPJ: A new long-acting formulation of the luteinizing hormone-releasing hormone analogue, goserelin: results of studies in prostate cancer. J Urol 155: 1352-1354, 1996.
7. 7. Kaisary AV, Tyrrell CJ, Peeling WB, and Griffiths K: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 67: 502-508, 1991.
8. 8. Vogelzang NJ, Chodak GW, Soloway MS, Block NL, Schellhammer PF, Smith JA, Caplan RJ, and Kennealey GT: Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology 46: 220-226, 1995.